These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31218668)

  • 1. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.
    Masur C; Soeberdt M; Kilic A; Knie U; Abels C
    Br J Dermatol; 2020 Jan; 182(1):229-231. PubMed ID: 31218668
    [No Abstract]   [Full Text] [Related]  

  • 2. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
    Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
    J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
    Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
    Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
    Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
    J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.
    Pariser DM; Lain EL; Mamelok RD; Drew J; Mould DR
    Clin Pharmacokinet; 2021 May; 60(5):665-676. PubMed ID: 33433785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.
    Siscos SM; Figenshau K; Rajpara A
    J Am Acad Dermatol; 2020 Oct; 83(4):e275. PubMed ID: 31846717
    [No Abstract]   [Full Text] [Related]  

  • 10. Qbrexza - A glycopyrronium cloth for axillary hyperhidrosis.
    Med Lett Drugs Ther; 2019 Jan; 61(1564):10-11. PubMed ID: 30856158
    [No Abstract]   [Full Text] [Related]  

  • 11. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
    Lamb YN
    Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study.
    Hyun MY; Son IP; Lee Y; Choi HG; Park KY; Li K; Kim BJ; Seo SJ; Kim MN; Hong CK
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):278-282. PubMed ID: 24909188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation.
    Kaufman AR; Gulati S; Curnyn KM
    Can J Ophthalmol; 2020 Oct; 55(5):464. PubMed ID: 32735775
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
    Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial.
    Szeimies RM; Abels C; Kilic A; Reich H; Berger B; Schulze Zur Wiesche E; Schramm K; Litzka L; Heimstaedt-Muskett S; Masur C
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):823-830. PubMed ID: 36606529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis.
    Pashaei-Marandi A; Assam JH; Arnold A; Lee AG; Bonelli L
    Can J Ophthalmol; 2019 Dec; 54(6):e300-e302. PubMed ID: 31836120
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study.
    Lueangarun S; Sermsilp C; Tempark T
    Dermatol Surg; 2018 Aug; 44(8):1094-1101. PubMed ID: 29659406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.